microRNA 3166 (MIR3166)

microRNA 3166 (MIR3166, hsa-mir-3166) is predicted to be a member of the microRNA family, consisting of short non-coding RNA molecules that regulate gene expression by binding to target mRNAs and promoting their degradation or suppressing translation[1][3][4]. Like other microRNAs, MIR3166 would be processed by the canonical DROSHA and DICER pathways to yield a mature form that can associate with the RNA-induced silencing complex (RISC)[1][4]. Mature animal microRNAs typically bind to the 3' untranslated region of target mRNAs, often through partial complementarity in the seed region, resulting in reduced protein output from those genes[1][3]. MicroRNAs broadly participate in the regulation of diverse biological processes including cell differentiation, proliferation, apoptosis, and may be detected extracellularly as circulating miRNAs which are researched as potential biomarkers[2][3]. However, there is a notable lack of published, structured, or functional data specifically for microRNA 3166 (MIR3166) itself. It does not appear prominently in curated microRNA databases, published studies, or clinical literature. This suggests MIR3166 may be a computational prediction, an orphon, or erroneously annotated, with no current evidence for therapeutic targeting, drug interactions, disease associations, or known safety concerns. **In summary:** There is insufficient evidence to confirm microRNA 3166 (MIR3166) as a true, biologically validated gene regulator or therapeutic target. Its listing may be spurious, outdated, or an annotation artifact, and it should be considered “incorrect” as a specific, actionable drug target entry. General information about microRNAs applies, but nothing is uniquely established about MIR3166 itself[3][4].

Other names

hsa-mir-3166MIR3166